Sugi Predict

Sugi Predict / Targets / NQO1

NQO1

NAD(P)H dehydrogenase [quinone] 1 · P15559 · NQO1 on Sugi Atlas →

30,668 patent compounds predicted against NQO1, 18,183 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29872 SCHEMBL29872 0.67 8/20
SCHEMBL310481 SCHEMBL310481 0.69 7/20
SCHEMBL669540 SCHEMBL669540 0.61 7/20
Tioclomarol Tioclomarol (SCHEMBL43646) 0.58 7/20
SCHEMBL669541 SCHEMBL669541 0.56 7/20
SCHEMBL578354 SCHEMBL578354 0.52 7/20
Dicumarol Dicumarol (SCHEMBL33891) 1.00 6/20
SCHEMBL187007 SCHEMBL187007 0.67 6/20
SCHEMBL669375 SCHEMBL669375 0.57 6/20
SCHEMBL103949 SCHEMBL103949 0.52 6/20
(3R)-Dunnione (3R)-Dunnione (SCHEMBL103115) 0.63 5/20
SCHEMBL647309 SCHEMBL647309 0.49 5/20
SCHEMBL122474 SCHEMBL122474 0.44 5/20
Ethyl Biscoumacetate Ethyl Biscoumacetate (SCHEMBL42830) 0.76 4/20
Tanshinone I Tanshinone I (SCHEMBL244391) 0.54 4/20
SCHEMBL753153 SCHEMBL753153 0.47 4/20
SCHEMBL753152 SCHEMBL753152 0.45 4/20
SCHEMBL429446 SCHEMBL429446 0.44 4/20
Tanshinone I Tanshinone I (SCHEMBL728081) 0.44 4/20
Coumetarol Coumetarol (SCHEMBL308833) 0.68 3/20

Clinical trials — most relevant to NQO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma PHASE4UNKNOWN
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis PHASE4NOT_YET_RECRUITING
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression PHASE2/PHASE3NOT_YET_RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age PHASE2COMPLETED
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia PHASE2UNKNOWN
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome PHASE1/PHASE2COMPLETED
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease PHASE2COMPLETED
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults PHASE2RECRUITING
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors PHASE1RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Lung Mucus Hypersecretion and NQO1 nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension nanRECRUITING
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) nanACTIVE_NOT_RECRUITING
NR Supplementation and Exercise nanCOMPLETED
The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults. nanUNKNOWN
Method Optimization for the Quantification of the NAD nanCOMPLETED
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects nanCOMPLETED
Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants nanCOMPLETED
Effectiveness of Qualia NAD+ Supplementation on NAD Levels nanCOMPLETED
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients nanUNKNOWN
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise nanCOMPLETED
Nicotinamide Riboside in Ulcerative Colitis nanRECRUITING
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NQO1 binder may also engage these)

ProteinNameSimilarity
Q5RD31 — 1.000 Q5RD31 →
Q64669 — 1.000 Q64669 →
P05982 — 1.000 P05982 →
Q8CHK7 — 0.997 Q8CHK7 →
Q9JI75 — 0.986 Q9JI75 →
NQO2 Ribosyldihydronicotinamide dehydrogenase [quinone] 0.986 landscape →
Q6AY80 — 0.984 Q6AY80 →
Q5RBB9 — 0.981 Q5RBB9 →
G6PD Glucose-6-phosphate 1-dehydrogenase 0.976 landscape →
Q803R5 — 0.973 Q803R5 →
A5GAC6 — 0.973 A5GAC6 →
Q3YA36 — 0.973 Q3YA36 →
P11605 — 0.973 P11605 →
P12646 — 0.972 P12646 →
NAT10 RNA cytidine acetyltransferase 0.972 landscape →
P11832 — 0.972 P11832 →
O55044 — 0.972 O55044 →
P11035 — 0.972 P11035 →
O88428 — 0.972 O88428 →
Q5ZJM3 — 0.971 Q5ZJM3 →
P39869 — 0.971 P39869 →
Q5R3I4 — 0.971 Q5R3I4 →
P54996 — 0.971 P54996 →
SMS Spermine synthase 0.971 landscape →
Q8N1G2 — 0.971 Q8N1G2 →
O57478 — 0.971 O57478 →
P0AEY7 — 0.971 P0AEY7 →
Q9SE94 — 0.971 Q9SE94 →
P39867 — 0.971 P39867 →
Q9SE60 — 0.971 Q9SE60 →